Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2012

Steinhardt James J, Gartenhaus Ronald B

Abstract excerpt

Currently, two major classification systems segregate diffuse large B-cell lymphoma (DLBCL) into subtypes based on gene expression profiles and provide great insights about the oncogenic mechanisms that may be crucial for lymphomagenesis as well as prognostic information regarding response to current therapies. However, these current classification systems primarily look at expression and not dependency and are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to NF-kappa B

Share to Precision Medicine

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-bcl-6

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 22745106
DOI: 10.1158/1078-0432.CCR-12-0217
PMCID: PMC3432648

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.PMID 22745106Read ↗

Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.Semantic proximity Read ↗

Decoding the Heterogeneity of Diffuse Large B-Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B-Cell Lymphoma Cell Lines.Semantic proximity Read ↗

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsSemantic proximity Read ↗

Molecular classification and therapeutics in diffuse large B-cell lymphomaSemantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular PhenotypeSemantic proximity Read ↗

Next-generation prognostic assessment for diffuse large B-cell lymphoma.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

A Genetic Predictive Model for Precision Treatment of Diffuse Large B-cell Lymphoma with Early ProgressionSemantic proximity Read ↗

Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.Semantic proximity Read ↗

The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implicationsSemantic proximity Read ↗

A prognostic signature based on ectopic reactivation of eight tissue-specific genes in Diffuse Large B Cell Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.